These biomarkers have been suggested to be key diagnostic criteria to defining AD although, at the same time, Abeta plaques and neurofibrillary deposits were acknowledged as perhaps not causal to AD pathogenesis (Jack et al., 2018). This evidence concerns the gene APP and Alzheimer disease.